基因内化物Rg3对心力衰竭的保护作用的药理机制
Yanan Jia1, Miao Gong1, Zunping Ke1
1Department of Geriatrics Shanghai Fifth People's Hospital Fudan University, Shanghai, China.
Cardiology research and practice
|August 7, 2024
概括
金色化物Rg3通过减少炎症,显示出对心力衰竭的心脏保护作用. 这种天然化合物向关键的炎症基因,为心血管疾病提供潜在的治疗益处.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心血管研究研究心血管研究
- 自然产品 自然产品
背景情况:
- 心力衰竭是心血管疾病的关键阶段.
- 人参化物Rg3正在研究其对心力衰竭的潜在保护机制.
研究的目的:
- 探索金色化物Rg3在预防心力衰竭中的药理机制.
- 确定潜在的药物疾病相互作用和关键分子标.
主要方法:
- 利用像SwissTargetPrediction和CTD这样的数据库来识别Ginsenoside Rg3目标和心力衰竭基因.
- 在重叠的基因上进行了基因本体学 (GO) 和KEGG通路丰富分析.
- 构建了一个蛋白质-蛋白质相互作用网络以识别枢纽基因 (STAT3,CASP3,TNF,IL-6).
- 在体外模型中验证了IL-6和TNF表达水平.
主要成果:
- 鉴定了15个Ginsenoside Rg3和心力衰竭之间的药物疾病相互作用基因.
- 丰富分析显示,与炎症相关的途径 (例如IL-6,TNF) 有显著的参与.
- 银化物Rg3治疗降低了H9c2细胞中IL-6和TNF水平的升高.
结论:
- 金色化物Rg3通过潜在的抗炎机制表现出心脏保护作用.
- 需要进行进一步的研究,才能充分阐明金赛诺Rg3在心力衰竭中的治疗潜力.
更多相关视频
05:57Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
Published on: May 17, 2024
697
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
3.4K
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
406
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
406
Heart Failure Drugs: Inotropic Agents
548
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
548
Heart Failure Drugs: Diuretics
353
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
353
Heart Failure Drugs: β-Blockers
326
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
326
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
